Zentalis Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance
Zentalis Pharmaceuticals, Inc. (ZNTL) had Deferred Tax Assets, Valuation Allowance of $281.98 million as of 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-03-26
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $281.98M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $247.03M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $219.29M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $160.97M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2025-12-31 | $281.98M 10-K · filed 2026-03-26 |
| 2024-12-31 | $247.03M 10-K · filed 2026-03-26 |
| 2023-12-31 | $219.29M 10-K · filed 2025-03-26 |
| 2022-12-31 | $160.97M 10-K · filed 2024-02-27 |
| 2021-12-31 | $97.16M 10-K · filed 2023-03-01 |
| 2020-12-31 | $56.26M 10-K · filed 2022-02-24 |
| 2019-12-31 | $28.65M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |